AMCR Stock Analysis: Amcor | NYSE
Packaging & Containers | NYSE, USA | Market Cap: 21.176m USD | 12M Return: 15.8% | JE00BV7DQ550 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 155M
EPS Trend: -22.0%
Qual. Beats: 0
Rev. Trend: 90.1%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amcor plc is a global packaging manufacturer headquartered in Zurich, Switzerland, that develops and produces packaging solutions primarily for the nutrition, health, beauty, and wellness categories across Europe, North America, Latin America, and the Asia Pacific. The company operates through two main segments: Global Flexible Packaging Solutions, which supplies polymer resin, aluminum, and fiber-based flexible packaging, and Global Rigid Packaging Solutions, which manufactures rigid containers, closures, and dispensing and pharma delivery devices. Its product portfolio spans bottles, vials, jars, films, laminates, tubes, trays, lids, tapes, and wipes packaging, among other items, sold through a direct sales force.
Founded in 1926 and listed on the NYSE in 2019, Amcor is classified within the Materials sector under the Metal, Glass & Plastic Containers sub-industry. Packaging companies in this segment typically generate revenue through high-volume, contract-based supply relationships with consumer goods manufacturers, with demand tied to underlying trends in packaged food, beverage, pharmaceutical, and personal care consumption worldwide.
- Berry Global merger closes, expanding global packaging scale
- Resin and aluminum cost volatility pressures packaging margins
- Healthcare rigid packaging segment grows on pharma demand
| Net Income: 1.09b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.18 > 1.0 |
| NWC/Revenue: 3.87% < 20% (prev 1.98%; Δ 1.89% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.84b > Net Income 1.09b |
| Net Debt (14.1b) to EBITDA (3.48b): 4.06 < 3 |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (464.6m) vs 12m ago 0.35% < -2% |
| Gross Margin: 19.07% > 18% (prev 18.96%; Δ 0.11% > 0.5%) |
| Asset Turnover: 64.57% > 50% (prev 46.84%; Δ 17.72% > 0%) |
| Interest Coverage Ratio: 3.44 > 6 (EBIT TTM 2.00b / Interest Expense TTM 583.0m) |
| A: 0.03 (Total Current Assets 8.36b - Total Current Liabilities 7.43b) / Total Assets 36.9b |
| B: 0.01 (Retained Earnings 459.0m / Total Assets 36.9b) |
| C: 0.05 (EBIT TTM 2.00b / Avg Total Assets 37.0b) |
| D: 1.46 (Book Value of Equity 36.9b / Total Liabilities 25.3b) |
| Altman-Z'' = 2.10 = BBB |
| DSRI: 0.80 (Receivables 3.75b/3.43b, Revenue 23.9b/17.4b) |
| GMI: 0.99 (GM 18.96% / 19.07%) |
| AQI: 1.10 (AQ_t 0.57 / AQ_t-1 0.52) |
| SGI: 1.37 (Revenue 23.9b / 17.4b) |
| TATA: -0.02 (NI 1.09b - CFO 1.84b) / TA 36.9b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of November 09, 2026, the stock is trading at USD 44.87 with a total of 4,384,040 shares traded. Over the past week, the price has changed by -5.32%, over one month by +7.42%, over three months by -3.28% and over the past year by +15.81%.
Current recommended Stop Loss: 43.10 (which is 3.9% or 1.3 ATR below the current price).
Amcor has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy AMCR.
- StrongBuy: 6
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 50.1 | 11.6% |
P/E Trailing = 20.3733
P/E Forward = 12.0773
P/S = 0.9009
P/B = 1.9003
P/EG = 1.1179
Revenue TTM = 23.9b USD
EBIT TTM = 2.00b USD
EBITDA TTM = 3.48b USD
Long Term Debt = 13.9b USD (from longTermDebt, last fiscal year)
Short Term Debt = 253.0m USD (from shortTermDebt, last quarter)
Debt = 15.0b USD (corrected: LT Debt 13.9b + ST Debt 253.0m) + Leases 852.0m
Net Debt = 14.1b USD (calculated: Debt 15.0b - CCE 832.0m)
Enterprise Value = 35.3b USD (21.2b + Debt 15.0b - CCE 832.0m)
Interest Coverage Ratio = 3.44 (Ebit TTM 2.00b / Interest Expense TTM 583.0m)
EV/FCF = 31.08x (Enterprise Value 35.3b / FCF TTM 1.14b)
FCF Yield = 3.22% (FCF TTM 1.14b / Enterprise Value 35.3b)
FCF Margin = 4.76% (FCF TTM 1.14b / Revenue TTM 23.9b)
Net Margin = 4.55% (Net Income TTM 1.09b / Revenue TTM 23.9b)
Gross Margin = 19.07% ((Revenue TTM 23.9b - Cost of Revenue TTM 19.3b) / Revenue TTM)
Gross Margin QoQ = 18.91% (prev 25.24%)
Tobins Q-Ratio = 0.96 (Enterprise Value 35.3b / Total Assets 36.9b)
Interest Expense / Debt = 3.90% (Interest Expense 583.0m / Debt 15.0b)
Taxrate = 14.12% (181.0m / 1.28b)
NOPAT = 1.72b (EBIT 2.00b * (1 - 14.12%))
Current Ratio = 1.12 (Total Current Assets 8.36b / Total Current Liabilities 7.43b)
Debt / Equity = 0.41 (Debt 15.0b / totalStockholderEquity, last quarter 36.9b)
Debt / EBITDA = 4.06 (Net Debt 14.1b / EBITDA 3.48b)
Debt / FCF = 12.44 (Net Debt 14.1b / FCF TTM 1.14b)
Total Stockholder Equity = 18.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.94% (Net Income 1.09b / Total Assets 36.9b)
RoE = 6.04% (Net Income TTM 1.09b / Total Stockholder Equity 18.0b)
RoCE = 6.30% (EBIT 2.00b / Capital Employed (Equity 18.0b + L.T.Debt 13.9b))
RoIC = 4.78% (NOPAT 1.72b / Invested Capital 36.0b)
WACC = 5.79% (E(21.2b)/V(36.1b) * Re(7.52%) + D(15.0b)/V(36.1b) * Rd(3.90%) * (1-Tc(0.14)))
Discount Rate = 7.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.22 | Cagr: 23.57%
[DCF] Terminal Value 74.54% ; FCFF base≈1.17b ; Y1≈1.11b ; Y5≈1.05b
[DCF] Fair Price = 5.31 (EV 16.6b - Net Debt 14.1b = Equity 2.45b / Shares 461.9m; r=8.35% [WACC [floored]]; 5y FCF grow -6.34% → 2.50% )
EPS Correlation: -22.00 | EPS CAGR: -2.28% | SUE: -0.23 | # QB: 0
Revenue Correlation: 90.12 | Revenue CAGR: 26.44% | SUE: 1.27 | # QB: 3
EPS current Quarter (2027-03-31): EPS=1.03 | Chg30d=-1.51% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=4.02 | Chg30d=-0.52% | Revisions=+0% | GrowthEPS=+12.8% | GrowthRev=+59.4%
EPS next Year (2027-06-30): EPS=4.28 | Chg30d=-0.23% | Revisions=-50% | GrowthEPS=+6.4% | GrowthRev=+1.0%
[Analyst] Revisions Ratio: -38% (up=1, down=4)